Compare
Alkermes vs Johnson & Johnson (ALKS vs JNJ)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Alkermes (ALKS) returned +47.7% and Johnson & Johnson (JNJ) +48.5%; so far this year the figures are +64.0% and +33.5%.
Johnson & Johnson is the larger company by market value, about 86.2 times the size of Alkermes.
Revenue grew +15.3% at ALKS and +7.8% at JNJ over the last year.
ALKS pays no dividend. JNJ yields 1.91%.
Data as of the latest close. Not investment advice.
Relative performance
| ALKS | JNJ | |
|---|---|---|
| Price | $45.90 | $276.22 |
| 1-day | +3.05% | +1.43% |
| YTD | +64.05% | +33.47% |
| 1 year | +47.73% | +48.51% |
| 3 years | +87.04% | +85.77% |
| Market cap | $7.7B | $665.0B |
| P/E | — | 41.9 |
| P/S | 4.40 | 6.69 |
| P/B | 4.14 | 8.16 |
| Revenue growth | +15.30% | +7.80% |
| EPS growth | -101.00% | -36.40% |
| Gross margin % | 82.9 | 67.6 |
| Net margin % | -0.0 | 16.2 |
| ROE % | -0.0 | 19.7 |
| Debt / equity | 0.80 | 0.55 |
| FCF yield % | 2.9 | 3.1 |
| Dividend yield % | — | 1.91 |
| Beta | 0.75 | -0.09 |
| RSI (14) | 59.9 | 59.4 |
| Technical rating |